Sarepta has completed the ESSENCE study, which is a confirmatory trial aimed at supporting full FDA approval of the exon-skipping PMOs Amondys 45 and Vyondys 53. The study did reinforce the favorable safety profile of the therapies, but did not achieve statistical significance on the primary endpoint (4-step ascend velocity at 96 weeks).
What comes next? Sarepta says it plans to discuss with the FDA a path from accelerated approval towards full approval, utilizing this data as well as real world evidence of these therapeutic approaches collected over multiple years.
Link to press release: https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-third-quarter-2025-financial
Community letter attached
The post Sarepta’s Amondys 45 and Vyondys 53 confirmatory trial fails to achieve statistical significance on primary endpoint appeared first on CureDuchenne.